BSECompany Update15h ago · 18 Nov 2026, 05:25 pm

Disclosure under Regulation 30 of SEBI (LODR)Regulations, 2015

3B BlackBio Dx Ltd · 532067

✦ AI SummaryM&A

3B BlackBio Dx Ltd, formerly known as Kilpest India Limited, has announced the acquisition of 100% shares of Bilex SRL, a Belgian company, for €274,817. The acquisition aligns with Coris BioConcept's commitment to long-term cost optimization and securing permanent infrastructure for its global diagnostic pipeline.

Analysis Scores

Earnings Impact5/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk6/10
Liquidity Impact9/10
Market Sentiment7/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

3B BlackBio Dx Ltd - 532067 - Disclosure Under Regulation 30 Of SEBI (LODR)Regulations, 2015

Attachments (1)

📄

fb022817-2412-41de-9b1e-1f8adad50ca1.pdf

pdf

Download →
View document text
(Formerly – Kilpest India Limited) Ref. No.P-66/2026-27/56 November 18th, 2026 The Relationship Manager, Department of Corporate Relations BSE Limited, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir / Madam, Sub: Intimation under SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 This is to inform you that Coris Bioconcept SRL (hereinafter referred to as “Coris”), subsidiary of 3B BlackBio Dx Ltd. (hereinafter referred to as “3B”) is pleased to announce that it has entered into a definitive agreement with Bilex SRL (hereinafter referred to as “Bilex”) to acquire 100% shares of the company. Bilex is the owner of land and building where the Coris office and manufacturing plant building is situated at Rue Guillaume Fouquet 11, 5032 Gembloux, Belgium. Coris shall acquire 100% of the total paid-up share capital of Bilex on November 18th 2026 from its shareholders Mr. Thierry Leclipteux and Mr. Joseph Bertinetti, and accordingly Bilex shall become a subsidiary of Coris as per the conditions set out in the Share Purchase agreement signed between the parties. The details required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure I. A business update on the aforesaid acquisition is enclosed as Annexure II for your perusal and information. Further, pursuant to Regulation 30 (8) of the SEBI LODR Regulations the enclosed disclosures and the business update are also made available on the company’s website. This is for your information and further dissemination. Thanking You, For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) Nikhil Kuber Dubey WholeTime Director DIN: 00538049 Encl: As above Regd. Office & Factory: 7-C | Industrial Area | Govindpura | Bhopal – 462023 | (M.P.) | INDIA CIN: L24211MP1972PLC001131 Ph.: 91-755-2586536, 2586537 Email: info@kilpest.com Visit us at: www.kilpest.com (Formerly – Kilpest India Limited) Annexure-I Disclosure under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026: S.No. Particulars Details a) Name of the Target Entity, details in Bilex SRL, Brief such as Size, Turnover etc.; 11, Rue Guillaume Fouquet, 5032 Isnes (Gembloux) BELGIUM Turnover (Rental Income) - €227,319.00 (FY’24) €232,267.05 (FY’25) b) Whether the acquisition would fall The acquisition does not fall within related within Related Party Transaction(s) party transactions. The promoter / promoter and whether the Promoter/ group have no interest in the entity being Promoter Group/ Group Companies acquired. have any interest in the Entity being acquired? If Yes, nature of interest and details thereof and whether the same is done at “Arm’s Length”; c) Industry to which the Entity being None – Owned/ Occupied Manufacturing acquired belongs; Building being acquired. d) Objects and Impact of Acquisition 1. At present, Coris is paying rent for the (including but not limited to, building. This acquisition transitions Coris Disclosure of Reasons for BioConcept from a tenant to an owner- Acquisition of Target Entity, if its occupier. Business is outside the main line of 2. By consolidating Bilex SRL accounts into Business of the listed entity); Coris, intercompany rental payments will get eliminated. 3. The restructuring will generate an immediate net annual savings of €140,000 before depreciation. Moving forward, the only property-related expense reflected on the consolidated financial statements will be the direct bank interest paid on Bilex’s long term loans apart from depreciation. e) Brief Details of any Governmental None or Regulatory Approvals Required for the Acquisition; f) Indicative Time Period for Acquisition to be completed on 18/11/ 2026 Completion of the Acquisition; g) Consideration - Whether Cash €274,817 cash consideration for 100% shares Consideration or Share Swap or of Bilex SRL along with payment of any Other Form and Details of the unsecured loan of €1.32 Million to two same; shareholders, and continuation of Bilex’s long-term building loans of €2.11 Million at an attractive average interest rate of 1.3 % payable in remaining 12 years. h) Cost of Acquisition and/or the Price Acquisition of 100% shares of Bilex SRL will at Which the Shares are Acquired; be acquired for €274,817. (Formerly – Kilpest India Limited) i) Percentage of Shareholding / 100% Equity Shares will be acquired by Coris Control Acquired and / or Number of from Bilex’s shareholders, Mr. Thierry Shares Acquired; Leclipteux(50%) and Mr. Joseph Bertinetti(50%). j) Brief Background about the Entity Bilex SRL, incorporated in 2014, which is the Acquired in terms of Products/Line owner of land and building where Coris office of Business Acquired, Date of and manufacturing plant is situated in Incorporation, History of last 3 years Belgium. Following the closing of this turnover, Country in which the transaction, Bilex SRL will operate as a Acquired Entity has presence and wholly-owned subsidiary of Coris any other Significant Information (in BioConcept. brief); This transaction aligns with Coris BioConcept's commitment to, long-term cost optimization, and securing the permanent infrastructure required to support its global diagnostic pipeline. Details of Revenue: Year Approx. Revenue (Rental Income) FY2023 €203,500.00 FY2024 €227,319.00 FY2025 €232,267.05 (Formerly – Kilpest India Limited) Annexure –II BUSINESS UPDATE: Coris BioConcept Announces Strategic Acquisition of 100% shareholding of Bilex SRL to Optimize Costs and Secure Facility Ownership November 18th 2026, Gembloux, BELGIUM: Coris BioConcept SRL, a leading innovator in rapid diagnostic kits for AMR, today announced a strategic agreement to acquire 100% of the shares of Bilex SRL from existing shareholders Mr. Thierry Leclipteux and Mr. Joseph Bertinetti. Bilex SRL is the owner of land and building where Coris office and manufacturing plant is situated. Following the closing of this transaction, Bilex SRL will operate as a wholly-owned subsidiary of Coris BioConcept. This corporate acquisition transitions Coris BioConcept from a tenant to an owner-occupier. By consolidating Bilex SRL into its corporate structure, intercompany rental payments will get eliminated. This ultra-modern building was built in 2023 is located in the Créalys® Science Park Gembloux on a 6,443 m2 land parcel. The building has a surface area of 2,000 m² which brings together the company’s administrative, offices and labs. It includes state-of-the-art laboratories equipped with containment airlocks and temperature- controlled and humidity-controlled environments. These are essential to ensure that research conducted here is accurate and safe. This building is equipped with 256 solar panels, two 20,000-litre rainwater-collection tanks to supply the bathrooms, a thermodynamic tank and optimized insulation. These installations reflect the company’s desire to minimize its environmental impact while continuing to develop. The restructuring will generate an immediate net annual savings of €140,000 before depreciation. Moving forward, the only property-related expense reflected on the consolidated financial statements will be the direct bank interest paid on Bilex’s existing long term building loans apart from depreciation. This transaction aligns with Coris BioConcept's commitment to, long-term cost optimization, and securing the permanent infrastructure required to support its global diagnostic pipeline. Mr. Sébastien Goenen (CEO – Coris Bioconcept SRL) said, “We are pleased to announce the acquisition of Bilex SRL. Transitioning from tenant to owner-occupier secures long-term control over our core operating infrastructure and delivers immediate, recurring savings to our cost base. Owning our Gembloux facility gives us the stability and flexibility to invest in our manufacturing capabilities and to scale operations in line with growing global demand for our rapid diagnostic solutions.” Mr. Dhirendr [Showing first 8,000 characters — download PDF for full document]